{
    "organizations": [],
    "uuid": "77386aed290e8a287fecbe254147599d0c74d395",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-lees-pharmaceutical-holdings-says/brief-lees-pharmaceutical-holdings-says-china-fda-grants-unit-approval-for-clinical-trials-idUSFWN1PO0DI",
    "ord_in_thread": 0,
    "title": "BRIEF-Lee's Pharmaceutical Holdings Says China FDA Grants Unit Approval For Clinical Trials",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 29 (Reuters) - Leeâ€™s Pharmaceutical Holdings Ltd :\n* CHINA FDA GRANTS UNIT APPROVAL FOR CLINICAL TRIALS FOR ITS RECOMBINANT HUMAN ANTI-PD-L1 MONOCLONAL ANTIBODY INJECTION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-29T19:26:00.000+02:00",
    "crawled": "2018-01-30T18:53:36.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "lee",
        "pharmaceutical",
        "holding",
        "ltd",
        "china",
        "fda",
        "grant",
        "unit",
        "approval",
        "clinical",
        "trial",
        "recombinant",
        "human",
        "monoclonal",
        "antibody",
        "injection",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}